Dr Véronique Walsh joins BMS
This article was originally published in Scrip
Executive Summary
Bristol-Myers Squibb has appointed Dr Véronique Walsh business unit director, neuroscience and immunoscience. She will lead the sales and marketing teams for the company's neuroscience and immunoscience portfolio, which includes Orencia (abatacept), Abilify (aripiprazole) and Perfalgan (paracetamol IV), as well as investigational products. Dr Walsh has 20 years' experience within the vaccines industry, most recently serving as deputy managing director in charge of market access, public affairs, communications, and strategic planning at Sanofi Pasteur MSD UK.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.